Key result
Ranolazine reduces complex PVCs and improves symptoms in a patient with arrhythmic MVP.
Why the study?
Pharmacological options for arrhythmic mitral valve prolapse are limited and anecdotal, and the antiarrhythmic role of ranolazine in this setting is unknown.
Does ranolazine reduce complex premature ventricular contractions in a patient with arrhythmic mitral valve prolapse?
Does ranolazine reduce complex premature ventricular contractions in a patient with arrhythmic mitral valve prolapse?
High-dose ranolazine may be an effective alternative for suppressing complex premature ventricular contractions in patients with arrhythmic mitral valve prolapse.
No takes yet. Share an insight, caveat, or question.
May warrant consideration in refractory arrhythmic MVP; hypothesis-generating and requires randomized trials before adoption.**[[1]](https://academic.oup.com/ehjcr/advance-article/doi/10.1093/ehjcr/ytag219/8528310)[[1]](https://academic.oup.com/ehjcr/advance-article/doi/10.
Tarantino et al. (2026) studied this question. Ranolazine 1000 mg twice daily objectively reduced complex premature ventricular contractions and improved symptoms over 32 months in a patient with arrhythmic mitral valve prolapse.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: